三氧化二砷治疗血液病后合并带状疱疹的临床研究

Clinical analysis of hematologic disorders complicated with herpes zoster after treating with arsenic trioxide

目的分析三氧化二砷（ATO）治疗血液病后合并带状疱疹感染患者的临床特征及其可能的发生机制。方法将研究对象分为研究组（应用ATO）和对照组（未应用ATO），观察两组带状疱疹发病率，以及研究组中发生带状疱疹和未发生带状疱疹患者的平均化疗次数。结果研究组带状疱疹发病率为23．95％（23／96），发生带状疱疹者平均化疗7．60次，未发生带状疱疹者平均化疗7．72次（Z=0．976，P=0．296）；对照组带状疱疹发病率7．89％（3／38），两组间带状疱疹发病率差异有统计学意义（x^2=4．492，P=0．034）。结论ATO治疗血液疾病可以增加带状疱疹的发病率，可能与其激活水痘一带状疱疹病毒有关。

Objective To explore the increasing risk of herpes zoster and its possible mechanisms for hematologic disorders treated with arsenic trioxide （ATO）. Methods The cases were divided into study group （with ATO） and control group （without ATO）. The incidence rate of herpes zoster was compared between the two groups, and then the average cycles of chemotherapy were compared between the patients complicated with herpes zoster or not in study group. Results The rate of herpes zoster was significantly higher in study group than that in control group （X^2 =4.492, P =0.034）. The rates of herpes zoster were 23.95 % （23/96） in study group and 7.89 % （3/38） in control groups. Patients in study group with herpes zoster had received 7.60 cycles and those without herpes zoster 7.72 cycles of chemotherapy on average （Z=0.976, P=0.296）. Conclusion The risk of herpes zoster complication in hematologic disorders was increased after ATO treatment which probably activated varicella-zoster virus.